Page 1 of 48
BARKLEY COMPREHENSIVE NP CERTIFICATION EXAM
2026/2027 COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
NP
Prepare for the Barkley Comprehensive NP Certification Exam with a focused study
resource covering essential concepts across major nurse practitioner practice
domains. It supports review of assessment, diagnosis, pharmacology, disease
management, preventive care, clinical decision-making, and evidence-based patient
care. Use the material to reinforce broad clinical knowledge, identify areas for
additional study, and build confidence for comprehensive certification preparation.
This resource is best suited for nurse practitioner students and certification
candidates preparing for comprehensive NP board-style examinations.
MULTIPLE CHOICE.
SECTION 1: HEALTH PROMOTION & DISEASE PREVENTION (Questions 1–
12)
Question 1:
According to the USPSTF, at what age should routine colorectal cancer
screening begin for average-risk individuals?
A) Age 40
B) Age 45
C) Age 50
D) Age 55
Answer: B) Age 45
Rationale: The USPSTF recommends routine colorectal cancer screening
begin at age 45 for average-risk individuals. This recommendation was
updated from age 50 to 45 in 2021. Screening options include colonoscopy
every 10 years, FIT annually, or stool DNA every 3 years. Age 40 (A) is
earlier than recommended; age 50 (C) was the previous recommendation;
age 55 (D) is later than recommended.
, Page 2 of 48
Question 2:
A 52-year-old woman with a 30-pack-year smoking history presents for a
health maintenance visit. Which of the following screening tests is indicated?
A) Chest X-ray annually
B) Low-dose CT scan annually
C) Sputum cytology annually
D) PET scan every 5 years
Answer: B) Low-dose CT scan annually
Rationale: Low-dose CT (LDCT) screening for lung cancer is recommended
annually for adults aged 50-80 with a ≥ 20 pack-year smoking history who
currently smoke or have quit within the past 15 years. Chest X-ray (A) and
sputum cytology (C) are not recommended for screening; PET scan (D) is
used for staging, not screening.
Question 3:
Which of the following vaccines is recommended annually for all adults?
A) Hepatitis B
B) Influenza
C) Tdap
D) MMR
Answer: B) Influenza
Rationale: Annual influenza vaccination is recommended for all adults
due to changing viral strains each year. Hepatitis B (A) is recommended for
specific risk groups; Tdap (C) is given once, then Td every 10 years; MMR
(D) is given in childhood (with catch-up for certain adults).
Question 4:
A 65-year-old patient asks about pneumococcal vaccination. Which of the
following is the recommended schedule?
A) PCV13 only
, Page 3 of 48
B) PPSV23 only
C) PCV13 followed by PPSV23 one year later
D) Both vaccines given simultaneously
Answer: C) PCV13 followed by PPSV23 one year later
Rationale: The CDC recommends PCV13 followed by PPSV23 at least one
year later for adults aged 65 and older (and for younger adults with certain
high-risk conditions). PCV13 provides protection against 13 serotypes;
PPSV23 provides broader coverage against 23 serotypes. If PPSV23 has
already been given, PCV13 should be given at least one year later.
Question 5:
A 30-year-old woman with no chronic conditions presents for a well-woman
exam. What is the appropriate recommendation for cervical cancer
screening?
A) Annual Pap smear
B) Pap smear every 3 years
C) HPV testing every 5 years
D) Both B and C are acceptable
Answer: D) Both B and C are acceptable
Rationale: For women aged 21-29, Pap smear every 3 years is
recommended. For women aged 30-65, co-testing (Pap + HPV) every 5
years is preferred, or Pap smear alone every 3 years is acceptable. Annual
Pap smears (A) are no longer recommended. Both B and C are acceptable
depending on the patient's age and preference.
Question 6:
A 12-year-old child presents for a well visit. She has not yet received the HPV
vaccine. The FNP should recommend:
A) One dose of HPV vaccine
B) Two doses of HPV vaccine (0 and 6-12 months)
, Page 4 of 48
C) Three doses of HPV vaccine
D) No vaccine because she is too young
Answer: B) Two doses of HPV vaccine (0 and 6-12 months)
Rationale: The CDC recommends a 2-dose schedule for HPV vaccination
if initiated before age 15. If started at age 15 or older, a 3-dose schedule is
used. The recommended age for routine HPV vaccination is 11-12 years,
but it can be started as early as age 9. Options A, C, and D are incorrect.
Question 7:
A 55-year-old woman of average risk asks when she can stop screening
mammography. According to the USPSTF, what is the recommendation?
A) Stop at age 65
B) Stop at age 70
C) Continue biennial screening through age 74, with individualized decisions
for women ≥ 75
D) Continue annual screening for life
Answer: C) Continue biennial screening through age 74, with
individualized decisions for women ≥ 75
Rationale: The USPSTF recommends biennial screening mammography
for women aged 50-74. For women ≥ 75, evidence is insufficient to assess
the balance of benefits and harms. The decision to continue screening
after age 74 should be individualized based on the patient's health status
and preferences. Options A, B, and D are not consistent with USPSTF
recommendations.
Question 8:
Which of the following is a modifiable risk factor for cancer?
A) Age
B) Genetic mutations
C) Tobacco use
D) Family history
BARKLEY COMPREHENSIVE NP CERTIFICATION EXAM
2026/2027 COMPLETE (100) CURRENT TESTING
QUESTIONS AND CORRECT ANSWERS WITH DETAILED
RATIONALES.
NP
Prepare for the Barkley Comprehensive NP Certification Exam with a focused study
resource covering essential concepts across major nurse practitioner practice
domains. It supports review of assessment, diagnosis, pharmacology, disease
management, preventive care, clinical decision-making, and evidence-based patient
care. Use the material to reinforce broad clinical knowledge, identify areas for
additional study, and build confidence for comprehensive certification preparation.
This resource is best suited for nurse practitioner students and certification
candidates preparing for comprehensive NP board-style examinations.
MULTIPLE CHOICE.
SECTION 1: HEALTH PROMOTION & DISEASE PREVENTION (Questions 1–
12)
Question 1:
According to the USPSTF, at what age should routine colorectal cancer
screening begin for average-risk individuals?
A) Age 40
B) Age 45
C) Age 50
D) Age 55
Answer: B) Age 45
Rationale: The USPSTF recommends routine colorectal cancer screening
begin at age 45 for average-risk individuals. This recommendation was
updated from age 50 to 45 in 2021. Screening options include colonoscopy
every 10 years, FIT annually, or stool DNA every 3 years. Age 40 (A) is
earlier than recommended; age 50 (C) was the previous recommendation;
age 55 (D) is later than recommended.
, Page 2 of 48
Question 2:
A 52-year-old woman with a 30-pack-year smoking history presents for a
health maintenance visit. Which of the following screening tests is indicated?
A) Chest X-ray annually
B) Low-dose CT scan annually
C) Sputum cytology annually
D) PET scan every 5 years
Answer: B) Low-dose CT scan annually
Rationale: Low-dose CT (LDCT) screening for lung cancer is recommended
annually for adults aged 50-80 with a ≥ 20 pack-year smoking history who
currently smoke or have quit within the past 15 years. Chest X-ray (A) and
sputum cytology (C) are not recommended for screening; PET scan (D) is
used for staging, not screening.
Question 3:
Which of the following vaccines is recommended annually for all adults?
A) Hepatitis B
B) Influenza
C) Tdap
D) MMR
Answer: B) Influenza
Rationale: Annual influenza vaccination is recommended for all adults
due to changing viral strains each year. Hepatitis B (A) is recommended for
specific risk groups; Tdap (C) is given once, then Td every 10 years; MMR
(D) is given in childhood (with catch-up for certain adults).
Question 4:
A 65-year-old patient asks about pneumococcal vaccination. Which of the
following is the recommended schedule?
A) PCV13 only
, Page 3 of 48
B) PPSV23 only
C) PCV13 followed by PPSV23 one year later
D) Both vaccines given simultaneously
Answer: C) PCV13 followed by PPSV23 one year later
Rationale: The CDC recommends PCV13 followed by PPSV23 at least one
year later for adults aged 65 and older (and for younger adults with certain
high-risk conditions). PCV13 provides protection against 13 serotypes;
PPSV23 provides broader coverage against 23 serotypes. If PPSV23 has
already been given, PCV13 should be given at least one year later.
Question 5:
A 30-year-old woman with no chronic conditions presents for a well-woman
exam. What is the appropriate recommendation for cervical cancer
screening?
A) Annual Pap smear
B) Pap smear every 3 years
C) HPV testing every 5 years
D) Both B and C are acceptable
Answer: D) Both B and C are acceptable
Rationale: For women aged 21-29, Pap smear every 3 years is
recommended. For women aged 30-65, co-testing (Pap + HPV) every 5
years is preferred, or Pap smear alone every 3 years is acceptable. Annual
Pap smears (A) are no longer recommended. Both B and C are acceptable
depending on the patient's age and preference.
Question 6:
A 12-year-old child presents for a well visit. She has not yet received the HPV
vaccine. The FNP should recommend:
A) One dose of HPV vaccine
B) Two doses of HPV vaccine (0 and 6-12 months)
, Page 4 of 48
C) Three doses of HPV vaccine
D) No vaccine because she is too young
Answer: B) Two doses of HPV vaccine (0 and 6-12 months)
Rationale: The CDC recommends a 2-dose schedule for HPV vaccination
if initiated before age 15. If started at age 15 or older, a 3-dose schedule is
used. The recommended age for routine HPV vaccination is 11-12 years,
but it can be started as early as age 9. Options A, C, and D are incorrect.
Question 7:
A 55-year-old woman of average risk asks when she can stop screening
mammography. According to the USPSTF, what is the recommendation?
A) Stop at age 65
B) Stop at age 70
C) Continue biennial screening through age 74, with individualized decisions
for women ≥ 75
D) Continue annual screening for life
Answer: C) Continue biennial screening through age 74, with
individualized decisions for women ≥ 75
Rationale: The USPSTF recommends biennial screening mammography
for women aged 50-74. For women ≥ 75, evidence is insufficient to assess
the balance of benefits and harms. The decision to continue screening
after age 74 should be individualized based on the patient's health status
and preferences. Options A, B, and D are not consistent with USPSTF
recommendations.
Question 8:
Which of the following is a modifiable risk factor for cancer?
A) Age
B) Genetic mutations
C) Tobacco use
D) Family history
